On April 12, 2024, T2 Biosystems, Inc., a medical device company, was the subject of a Schedule 13G filing with the United States Securities and Exchange Commission. The filing indicated that New Dimensions Trading Ltd., based in the Cayman Islands, and Jacob Safier, a United States citizen, have reported beneficial ownership of T2 Biosystems' common stock. Both New Dimensions and Safier reported sole voting and dispositive power over 755,000 shares, representing 4.3% of the company's class of securities based on 17,479,954 shares outstanding as reported in T2 Biosystems' Quarterly Statement on Form 10-Q filed on August 8, 2024. The filing, made under Rule 13d-1(c), certifies that the shares were not acquired for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect. The certification was signed by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier on August 15, 2024.

On April 12, 2024, T2 Biosystems, Inc., a medical device company, was the subject of a Schedule 13G filing with the United States Securities and Exchange Commission. The filing indicated that New Dimensions Trading Ltd., based in the Cayman Islands, and Jacob Safier, a United States citizen, have reported beneficial ownership of T2 Biosystems' common stock. Both New Dimensions and Safier reported sole voting and dispositive power over 755,000 shares, representing 4.3% of the company's class of securities based on 17,479,954 shares outstanding as reported in T2 Biosystems' Quarterly Statement on Form 10-Q filed on August 8, 2024. The filing, made under Rule 13d-1(c), certifies that the shares were not acquired for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect. The certification was signed by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier on August 15, 2024.